Gut microbiome changes linked to onset of rheumatoid arthritis among at-risk individuals

HOUSTON — An investigational oral drug targeting the lack of brain orexin neuropeptides that characterizes narcolepsy type 1 demonstrated safety and effectiveness for the condition

Spanish-headquartered Minoryx Therapeutics says the U.S. Food and Drug Administration (FDA) has approved its phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat